SUMMARY Background
Chronic hepatitis C virus therapy in patients with advanced liver disease remains a clinical challenge. HCV-TARGET collects data in patients treated at tertiary academic and community centres.
Aim
To assess efficacy of all-oral HCV therapy in advanced liver disease.
Methods
Between December 2013 and October 2014, 240 patients with a MELD score of ≥10 initiated HCV treatment with an all-oral regimen. Data from the 220 patients who completed 12-week follow-up were analysed.
Results
Genotype 1 (GT1) patients had higher sustained virological response (SVR) when treated with sofosbuvir plus simeprevir AE ribavirin than with sofosbuvir plus ribavirin (66-74% vs. 54%); GT1b vs GT1a (84% vs. 64%). SVR for GT2 was 72% with sofosbuvir plus ribavirin, while GT3 patients had a substantially lower response (35%). A decrease in MELD score was not clearly related to SVR over the short course of follow-up although some had improvements in MELD score, serum bilirubin and albumin. A predictor of virological response was albumin level while negative predictors were elevated bilirubin level and GT1a. Most patients with GT1 were treated with approximately 12-week duration of sofosbuvir and simeprevir AE ribavirin therapy while GT2 and GT3 patients were treated with approximately 12 and 24 weeks of sofosbuvir plus ribavirin respectively.
INTRODUCTION
Hepatitis C virus (HCV) infection is a progressive disease leading to fibrosis, cirrhosis, hepatocellular carcinoma (HCC) and liver failure.
1, 2 HCV mortality rates have eclipsed those of the human immunodeficiency virus (HIV) infection in USA, and the disease burden resulting from HCV is predicted to further increase over the next decade. [3] [4] [5] On a positive note, successful treatment of HCV has been associated with a decrease in allcause mortality and HCC. 6, 7 However, it remains unknown whether treatment of HCV in those with advanced or decompensated liver disease will lead to improved liver function analogous to previous observations in those with hepatitis B virus (HBV)-related liver disease after the initiation of HBV therapy. 8 Hitherto, interferon (IFN)-based therapies presented major challenges in patients with advanced cirrhosis with poor tolerability, high rates of adverse events, and suboptimal response rates. 9, 10 To that end, effective, better tolerated treatments were felt to be urgently needed for these patients. Sofosbuvir, a nucleotide NS5B polymerase inhibitor, in combination with ribavirin, has shown excellent responses with good safety and tolerability in those with cirrhosis, providing a much needed IFN-free regimen for these difficult-to-treat patients. [11] [12] [13] Combination therapies including NS3/4A (grazoprevir), NS5A (ledipasvir, daclatasvir and elbasvir) and NS5B polymerase (sofosbuvir) inhibitors have demonstrated high efficacy and good tolerability largely in clinical trials in patients with advanced liver disease. [14] [15] [16] In the USA, regimens containing sofosbuvir and simeprevir (an NS3/ 4A protease inhibitor) were approved in 2013 for treatment of chronic HCV, but not for treatment in patients with decompensated liver disease. 17, 18 Yet, based on a single phase II study of sofosbuvir plus simeprevir showing excellent results in patients with well-compensated liver disease, this regimen presented an option for patients with more advanced liver disease. 19, 20 With several options becoming available in this important population, HCV-TARGET, a consortium dedicated to collecting and evaluating clinical care data, assessed the use and outcomes of all-oral therapies in patients with advanced liver disease.
METHODS
Patients and study design HCV-TARGET is an international consortium of academic (N = 39) and community (N = 13) medical centres in USA, Germany, Israel and Canada conducting a longitudinal, observational study to investigate the effects of direct-acting antiviral agents (DAAs) in the clinical setting. HCV patients aged 18 years and older were included if they had been treated with an all-oral DAA regimen according to standard of care at the local study sites. To be included in this assessment, patients were required to have a baseline model for end-stage liver disease (MELD) score greater than or equal to 10, have no prior liver transplant history, and have available treatment outcome. In contrast to Phase II and III clinical trials, there were no parameters for demographics, treatment regimen/duration or safety management outlined by the study protocol. The primary aim of the analysis was to evaluate sustained virological response defined as HCV RNA below level of quantitation approximately 12 weeks after cessation of therapy (SVR). To account for variability in clinic visits in clinical practice, the window for HCV RNA assessment for SVR was 9 or more weeks following cessation of treatment. Other analyses included safety of the regimens, response rates by genotypes and severity of liver disease based on MELD scores, predictors of response and changes in hepatic function over the short term.
Data from sequentially enrolled patients treated with one of three all-oral, DAA-based therapies were included in this analysis: sofosbuvir plus ribavirin, sofosbuvir plus simeprevir, or sofosbuvir plus simeprevir and ribavirin. These treatments were administered at the discretion of local caregivers. Redacted medical records during treatment and the post-treatment follow-up periods, including demographic, adverse event and virological data, were collected from sites by a central team of trained coders, reviewed and the data were entered into a common, standardised database using novel source data extraction methods. Data were managed using REDCap electronic data capture tools hosted at UNC Chapel Hill. 21 Data were reviewed and confirmed for completeness and accuracy by independent monitors. Records were screened for extreme or unlikely values. These instances were verified or resolved with additional queries. Data from the treatment and follow-up periods of patients treated with DAAs were included in the current analysis. The local Institutional Review Boards (IRB) at all participating sites approved this study. Patients provided written informed consent, or were enrolled under a waiver of consent per local IRB policies. All authors had access to the study data and reviewed and approved the final manuscript.
Definitions of AE and SAE Adverse event (AE). (i) Any event that required a dose reduction in HCV medication, discontinuation of HCV therapy, or the addition of a concomitant medication for management or (ii) any event of special interest (e.g. rash, anaemia, photosensitivity, jaundice, further hepatic decompensation), regardless of management at any time during treatment.
Serious adverse event (SAE). An AE that either (i) required hospitalisation, or (ii) met criteria for expedited reporting per FDA form MEDWATCH 35000.
Anaemia. The presence of any of the following: (i) anaemia reported as an AE by a healthcare professional, (ii) administration of red blood cell growth factors or (iii) patient received a transfusion. History of hepatic decompensation. Presence of current or past ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatic hydrothorax or variceal haemorrhage or concomitant medications specifically indicated for any of the above at the time of treatment start.
Statistical analysis
Virological response, relapse rate and frequencies of adverse events were collected for the study population and analysed according to discrete subpopulations of interest. All analyses were performed for two subgroups -MELD 10-15 and >15. Confidence intervals of unadjusted rates were calculated using exact binomial methods. Changes in laboratory values (MELD, albumin and total bilirubin) were calculated from baseline to posttreatment week 9 or later. A set of multivariable analyses of predictors of SVR was run for GT1 sofosbuvir/ simeprevir and sofosbuvir/simeprevir/ribavirin patients, and measures of association between baseline covariates and SVR were estimated with logistic regression with the predictor of interest, age and gender in the model.
The predictor variables included in multivariable models were selected before and included the most well-established baseline covariates associated with SVR: treatment regimen, previous treatment experience, gender, age <60 years, race, GT1 subtype, MELD, albumin (g/ dL), platelet count, creatinine clearance, total bilirubin (mg/dL), haemoglobin (g/dL) and international normalised ratio (INR). Results are presented with an odds ratio, 95% confidence intervals and P-values. Sensitivity analyses replacing albumin as a continuous variable, and as a categorical variable using different thresholds between 3.5 g/dL and 2.6 g/dL were also performed. Analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS

Patients and treatments
A total of 1685 of the 2105 patients screened for HCV-TARGET who started treatment between December 2013 and October 2014 were treated with sofosbuvir plus ribavirin, sofosbuvir plus simeprevir, or sofosbuvir plus simeprevir and ribavirin. Of these, 240 patients had a MELD score of greater than or equal to 10 at the initiation of treatment and no prior history of liver transplant. At the time of analyses, four patients were still on treatment and 16 patients remained in post-treatment followup. Treatment outcomes were available for 220 patients, which comprises the study population. Across all groups, 93.2% of patients completed a full course of therapy while only 6.8% discontinued therapy prematurely. This included 3.6% who discontinued due to adverse events ( Table 1) .
The demographic and baseline biochemical and virological characteristics of the study population are shown in Table 2 . Median age for the population was 60 years (range 38-80 years) and the majority of patients were male (65%). One hundred and thirty-two patients (60.0%) were treatment-experienced, 8.2% of the overall cohort and 13.6% of the treatment-experienced patients had previously failed a protease inhibitor based regimen, and 161 (73.2%) had a prior history of hepatic decompensation, reflecting the severity of their liver disease. There were 157 patients with GT1, 26 with GT2 and 31 patients with GT3 (Table 2) .
Patients were categorised into two groups reflecting increasing severity of liver disease: patients with MELD from 10 to 15 (N = 192) and patients with MELD >15 (N = 28). The distribution of MELD scores across treatment regimens is shown in Table 2 .
Treatment duration
The overall treatment duration of sofosbuvir plus simeprevir AE ribavirin for GT1 patients ranged from 2 to 48 weeks, with a median of 12 weeks and a mean of 14.4 weeks. There was no difference in the ribavirincontaining and ribavirin-free regimens (median 12 weeks; mean 13.5 and 12 weeks respectively). When analysed by SVR and failure, the treatment duration was similar to the overall GT1 population. GT2 and GT3 patients overall were treated with sofosbuvir and ribavirin [GT2 had median 12 weeks (range 12-24 weeks), mean 13.7 weeks; GT3 had median 24 weeks (range 7-26 weeks), mean 22.7 weeks]. Similar to GT1, treatment duration in GT2 and GT3 patients was not different in those who either achieved SVR or were nonresponders.
Sustained virological response and relapse rates
The SVR and relapse rates for the overall population and various subpopulations are shown in Figure 1 . SVR in GT1. GT1 patients had a numerically higher SVR rate when treated with sofosbuvir plus simeprevir than those treated with sofosbuvir and ribavirin [74% (95% CI: 64-82) vs. 54% (95% CI: 33-73) respectively]. The addition of ribavirin to the sofosbuvir plus simeprevir combination had no discernable effect on SVR outcome [sofosbuvir/simeprevir/ribavirin: 66% (95% CI: 46-82)]. Patients treated with sofosbuvir and ribavirin regimen had the most pronounced numerical difference in SVR between treatment-na€ ıve and treatment-experienced GT1 patients 60% (95% CI: 26-88) vs. 50% respectively (95 CI: 25-75). SVR rates were similar between treatmentna€ ıve and -experienced patients in the regimens with sofosbuvir plus simeprevir with or without ribavirin (Figure 1) .
SVR in the MELD groups. Sustained virological response data were also analysed according to MELD group. In patients with a MELD score of 10-15, 37/74 (50%) treated with sofosbuvir and ribavirin, 66/91 (73%) treated with sofosbuvir plus simeprevir, and 18/27 (67%) treated with sofosbuvir/simeprevir/ribavirin achieved SVR. In patients with a MELD score greater than 15, 6/11 (55%, CI; 23-83) treated with sofosbuvir and ribavirin, 9/12 (75%, CI: 43-95) treated with sofosbuvir/simeprevir, and 4/5 (80%, CI: 28-99) treated with sofosbuvir/simeprevir/ ribavirin achieved SVR. Viral relapse was the most important reason for treatment failure with relapse rates lowest in GT2 patients (2/26, 8%) intermediate in GT1
patients (44/157, 28%), and highest in GT3 patients (17/ 31, 55%).
Predictors of outcome, and change in MELD, total bilirubin and albumin A set of multivariable analyses was conducted to examine predictors of SVR among GT1 patients treated with sofosbuvir and simeprevir and sofosbuvir/simeprevir/ribavirin ( Figure 2) ; each analysis includes only one predictor listed in the figure, age-and sex-adjusted. Patients who discontinued treatment prematurely for nonvirological reasons were excluded from the analysis. Albumin level at baseline (OR: 2.46, 95% CI: 1.10-5.51, P = 0.03) was the strongest predictor of achieving an SVR while elevated bilirubin was the strongest negative predictor of SVR (OR: 0.45, 95% CI: 0.28-0.73, P = 0.001). Performing sensitivity analysis replacing albumin as a continuous variable with categorical variable using different thresholds between 3.5 g/dL and 2.6 g/dL revealed that the albumin level of 2.8 g/dL or lower was associated with lesser odds of achieving SVR, although the number of patients in some categories was small (data not shown). Patients with GT1a infection trended towards being less likely to achieve SVR (OR: 0.42, 95% CI: 0.16-1.12, P = 0.08). Of note, while elevated bilirubin levels were associated with negative outcomes, a patient's MELD score was not an independent predictor of response.
To assess the impact of SVR on liver disease severity, changes in MELD, total bilirubin and albumin were analysed from baseline to post-treatment week 9 or later based on available data. MELD scores for patients were generally improved or stable (95/137, 69%) and improvement was observed more frequently after treatment success (Figure 3a ,b and Table S2 ). In those with baseline MELD 10-15, 58/122 (48%) patients exhibited a decrease in MELD score. Forty one of eighty-five (48%) of the patients with MELD 10-15 who achieved SVR and 17/37 (46%) of those who failed therapy showed improvement in MELD score. In patients with a baseline MELD >15, all patients who achieved SVR exhibited an improvement in MELD compared to those who failed, 8/8 (100%) vs. 4/7 (57%) respectively.
Changes in total bilirubin were likewise generally improved or stable. Of patients with evaluable MELD change and a baseline MELD of 10-15 (85 achieved SVR and 37 failed therapy), there was a decreased total bilirubin in 52/122 (43%) patients and an increase in 26/122 (21%) patients; among the 85 who had achieved SVR, 37 (44%) had a decrease in bilirubin vs. 15 Table S2 ). After treatment, there was a trend towards higher levels of serum albumin in a majority of study participants (Figure 5a ,b and Table S2 ). In patients with available albumin change (n = 151) and a baseline MELD of 10-15 (n = 122), 55 (42%) patients showed an increase in albumin and only 17 (13%) patients decreased serum albumin. In patients with MELD >15 (N = 19), albumin increases were observed in 53%, while a decrease was observed in two patients (11%). In the group who achieved SVR in both the MELD 10-15 and MELD >15 groups, more patients had increased albumin (44% and 69%) compared to virological failures (38% and 17%) respectively; however, the difference was not statistically significant (P = 0.21).
Adverse events (Tables S3-S5 ): In total, 190 of 220 patients experienced at least one AE: 77/85 (90.6%) patients treated with sofosbuvir/ribavirin, 84/103 (81.6%) patients treated with sofosbuvir and simeprevir, and 29/ 32 (90.6%) patients treated with sofosbuvir/simeprevir/ ribavirin. AEs that were present in more than 10% of patients are available in Table S3 . Anaemia occurred in 40/117 (34%) of patients treated with ribavirin compared to 3.9% treated with sofosbuvir/simeprevir only (Table S4) . Among patients treated with a ribavirin-containing regimen, 9% received epoietin, and 7% required blood transfusion. Those on a simeprevir-based regimen exclusively reported photosensitivity (6% of those receiving sofosbuvir/simeprevir only and 13% of patients treated with a ribavirin-containing regimen, not shown in table). A total of 41 (18.6%) patients experienced at least one serious adverse event while on treatment (Table S3) for a total of 65 SAE events; 15 of these were events of hepatic decompensation (sofosbuvir/ribavirin: 10, sofosbuvir/simeprevir: 2, sofosbuvir/simeprevir/ribavirin: 3).
In the sofosbuvir/simeprevir group, one patient died of hepatic failure, and in the sofosbuvir/simeprevir/ribavirin group, one patient expired due to unspecified causes (Table S5) . Nine patients (4%) underwent liver transplantation (LT) during their course of therapy. Two discontinued planned therapy because of liver transplant, three had LT while on treatment, two had LT after end of treatment and two completed therapy the same day as LT. Seven patients achieved SVR; one had relapse and one was considered lost to follow-up.
DISCUSSION
This large observational, real-world study assessed the use of all-oral, sofosbuvir-based HCV therapies in patients with advanced liver disease. Clinical care data for patients treated at tertiary academic and community centres and without predefined criteria for treatment regimen and duration were collected and analysed. The observations indicate that all-oral, and largely sofosbuvirand simeprevir-based therapeutic regimens for GT1 HCV in those with advanced liver disease (defined as MELD ≥10) are effective and safe and thus reassuring that observations from clinical trials can be substantiated in clinical practice. While simeprevir is not recommended for use in patients with advanced liver disease, 22 it was used in this patient population (defined as MELD ≥10) at a time when approved all-oral regimens were unavailable for GT1 patients with advanced disease and clinicians used these drugs in patients, they perceived to be at high risk for liver complications in the absence of therapy. 20 In patients with advanced liver disease, IFN-based therapies are either contraindicated, not well tolerated, or associated with low SVR rates of approximately 30%. 23, 24 In our experience, SVR rates with oral therapy in GT1 patients were 54%, 74% and 66% after treatment with sofosbuvir and ribavirin, sofosbuvir plus simeprevir, and sofosbuvir/simeprevir/ribavirin respectively. These rates compare favourably with those from clinical trials and compassionate use programmes of all-oral therapy treating patients with advanced liver disease. 14-16, 21, 25-29 Although the recommended duration of therapy for those with compensated cirrhosis (while this regimen is not recommended for those with advanced liver disease) with sofosbuvir/simeprevir AE ribavirin is for 24 weeks, most patients were treated for close to 12 weeks. The impact of duration and the addition of ribavirin cannot be assessed reliably in this cohort given the small number of patients treated with extended duration and with ribavirin. Although not significant, GT1a HCV infection had a trend towards being a negative predictor of response (P = 0.08) among GT1 patients in multivariable analysis. Simeprevir-based therapy has been noted to have a blunted response in patients with GT1a infection and the presence of Q80K mutation. This has been observed in close to half of North American patients. 30 While it is recommended that Q80K mutation be tested for in GT1a patients prior to the use of simeprevir with peg-interferon and ribavirin, less than 10% of patients were tested in the context of all-oral therapy in clinical practice. Furthermore, 8.2% of the overall cohort who had previously failed a PI-based regimen were retreated with another PI-containing regimen, suggesting that physicians are willing to use available therapeutic options for these at-risk patients regardless of concerns regarding baseline resistance. Both GT2 and GT3 patients were treated with sofosbuvir and ribavirin for close to the duration recommended in the label for those with compensated liver disease, but for shorter than the 48 weeks duration as per the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America for those with advanced liver disease.
18 GT2 patients treated with sofosbuvir and ribavirin achieved an SVR of 72% (18 of 25 patients) despite the advanced liver disease present in this patient population. These data in patients with GT2 mimic SVR rates in clinical trials and in patients with well-compensated liver disease, reassuring the observation that GT2 is readily treatable regardless of the severity of liver disease [31] [32] [33] However, patients with GT3 HCV treated with sofosbuvir and ribavirin experienced low response rates of 36% and a high relapse rate of 55%; any benefit of longer duration could not be assessed. GT3 is more frequent in certain parts of the world such as India and Pakistan and advanced liver disease is likely to represent a large population without the option of liver transplantation. A drug that is effective against GT3 that is becoming increasingly available in various parts of the world is daclatasvir, a pan-genotypic NS5A inhibitor. The combination of daclatasvir and sofosbuvir AE ribavirin is much more effective than sofosbuvir and ribavirin, and several experiences globally have demonstrated the efficacy of this regimen. 28, 29 This drug has only recently been approved in the USA and thus large experiences, from clinical experiences, have not been published from the USA. After successful completion of treatment, improvements or stability in MELD scores, bilirubin levels and albumin levels were observed. Among those with a higher baseline MELD over 15, improvement in MELD score was seen more frequently in those who achieved SVR, although there were overlapping changes in those with and without SVR. Furthermore, serum albumin appeared to increase from baseline values more frequently among those who achieved SVR, regardless of baseline MELD score. However, SVR was not always associated with an improvement, as some patients continued to deteriorate clinically. Such observations have been made during short-term follow-up in clinical trials as well. 14, 16, 26 Similar overall trends were observed with total bilirubin and albumin levels. A decrease in total bilirubin and an increase in albumin were observed, and more patients who achieved SVR exhibited improvements in both analyses. Thus, short-term follow-up data are not sufficient to gauge the impact of SVR on improvement in hepatic function and long-term followup of these patients will be critical to help develop predictors of important clinical outcomes (improvement vs. decompensation) associated with treatment intervention, which can serve to guide physicians on selecting candidates for treatment and optimising listing for liver transplantation. Although simeprevir is not recommended for use in those with advanced liver disease, it was used liberally in this experience. Simeprevir is an inhibitor of bile transporters (OATP1B1/3) and thus is known to cause mild unconjugated hyperbilirubinemia even in patients with well-compensated liver disease. 20 Thus, there would be a concern of accentuated hyperbilirubinemia in patients with advanced liver disease. Therefore, we carefully assessed the safety profile. There were 65 SAEs, 16 of which were events of hepatic decompensation, four of them (in three patients) were considered to be associated with the treatment. Ten patients developed SAE infections, a common event in those with advanced liver disease. There were two deaths during the study period.
One was attributed to hepatic failure, and another unspecified. Based on the advanced nature of liver disease and the patients being prone to several complications, it is challenging to establish causality between the serious adverse events and the DAAs.
In summary, all-oral, sofosbuvir-based HCV therapy in GT1 or GT2 patients with advanced liver disease presents a good option. Real-life data on SVR are encouraging and helps in improvement in severity of liver disease in most patients. It is unclear, based on short follow-up period, what the long-term benefits might be, and what baseline and on-treatment predictors might address potential benefit vs. harm. Long-term follow-up is needed to more convincingly address the benefits of eradicating HCV infection in those with advanced liver disease. While ledipasvir, an NS5A inhibitor and sofosbuvir combination has been the treatment of choice in GT1 patients, this combination is unfortunately not available in several countries. Ledipasvir and sofosbuvir have worked effectively in patients with decompensated liver disease. 16, 26 However, in some countries such as
Brazil with a large hepatitis C population, sofosbuvir and simeprevir are available while ledipasvir is not and thus sofosbuvir and simeprevir combination serves as an effective therapeutic option. Furthermore, with the wide spread use of the NS5A and sofosbuvir combination, there has been the emergence of NS5A resistance, thus making the protease inhibitor, simeprevir and sofosbuvir a viable rescue strategy. Also these data are relevant to regions of the World, where generic sofosbuvir is available and potentially simeprevir can be used in combination with success.
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